4:11 PM ET
8-K
Divestiture
ZeroStack Divestiture to New Horizon Pharma B.V.
ZeroStack Corp. entered into a definitive agreement to sell 100% of its subsidiary, Phatebo GmbH, to New Horizon Pharma B.V. for an aggregate purchase price of €2,150,000. The closing of the transaction is subject to foreign direct investment clearance in Germany and other customary closing conditions.
- Counterparty
- New Horizon Pharma B.V.